KAINOS Laboratories, Inc. Stock

Equities

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
1,212 JPY +0.17% Intraday chart for KAINOS Laboratories, Inc. +2.28% +11.09%
Sales 2009 3.59B 22.69M Sales 2010 4.22B 26.61M Capitalization 1.4B 8.85M
Net income 2009 168M 1.06M Net income 2010 101M 638K EV / Sales 2009 0.43 x
Net Debt 2009 893M 5.64M Net Debt 2010 909M 5.74M EV / Sales 2010 0.55 x
P/E ratio 2009
3.96 x
P/E ratio 2010
13.8 x
Employees 133
Yield 2009
2.68%
Yield 2010
2.38%
Free-Float 38.54%
More Fundamentals * Assessed data
Dynamic Chart
KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021. CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million. CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million. CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan. CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020. CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2020, has closed with 88,000 shares, representing 2.02% for ¥90.29 million. CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 90,000 shares, representing 2.02% for ¥100 million. CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan. CI
KAINOS Laboratories, Inc. announced that it has received ¥435.12 million in funding from Asahi Kasei Pharma Corporation CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥435.12 million in funding from Asahi Kasei Pharma Corporation CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on September 25, 2018. CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on September 25, 2018 has expired with 490,800 shares, representing 11.01% for ¥541.35 million. The company repurchased 490,800 shares from Hitachi Chemical Company, Ltd.. CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 500,000 shares, representing 11.22% for ¥551.5 million. CI
More news
1 day+0.17%
1 week+2.28%
Current month+1.25%
1 month-0.82%
3 months+1.85%
6 months+18.13%
Current year+11.09%
More quotes
1 week
1 190.00
Extreme 1190
1 227.00
1 month
1 160.00
Extreme 1160
1 240.00
Current year
1 055.00
Extreme 1055
1 289.00
1 year
1 000.00
Extreme 1000
1 289.00
3 years
929.00
Extreme 929
1 945.00
5 years
681.00
Extreme 681
2 047.00
10 years
453.00
Extreme 453
2 047.00
More quotes
Managers TitleAgeSince
President 64 82-03-31
Chief Tech/Sci/R&D Officer - -
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 -
President 64 82-03-31
Chief Administrative Officer 62 93-09-30
More insiders
Date Price Change Volume
24-04-26 1,212 +0.17% 3,400
24-04-25 1,210 -0.08% 16,700
24-04-24 1,211 +0.58% 1,900
24-04-23 1,204 +1.01% 4,100
24-04-22 1,192 +0.59% 2,200

Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT

More quotes
KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.
Calendar
More about the company